SCHEMBL2226684

SCHEMBL2226684

CN(C)CC(C)(C)CNC(=O)c1ccc2c(Cl)c3c(nc2c1)CCCC3

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.64
TP53 P04637 2/20 0.64
SMN1; SMN2 Q16637 4/20 0.62
HTT P42858 2/20 0.62
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
USP7 Q93009 1/20 0.59
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
GAA P10253 1/20 0.58
GFER P55789 1/20 0.58
ALDH1A1 P00352 2/20 0.58
POLB P06746 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228017 0.87 MAPT (0.52) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2228012 0.87 MAPT (0.52) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2217604 0.84 SMN1; SMN2 (0.75) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL20864349 0.79 MAPT (0.73) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2221128 0.78 SMN1; SMN2 (0.89) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2219373 0.78 KMT2A (0.86) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2218247 0.77 SMN1; SMN2 (1.00) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL31069697 0.76 MEN1 (0.96) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL2218102 0.76 MEN1 (0.96) MAPTTP53SMN1; SMN2HTTNPC1
SCHEMBL31069695 0.76 MEN1 (0.96) MAPTTP53SMN1; SMN2HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US claimed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885TP53 330/4885SMN1; SMN2 2877/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885TP53 330/4885SMN1; SMN2 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.